Sildenafil Tablet, Film Coated
Product Images NDC 72789-103

10 FDA label images from Pd-rx Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 72789-103). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Sildenafilchemicalstructure (Sildenafilchemicalstructure)

Sildenafilchemicalstructure (Sildenafilchemicalstructure)
Chemical structure diagram of Sildenafil, showing the molecular arrangement including aromatic rings, nitrogen atoms, and carboxyl groups.*
FDA Label Image

Sildenafilfig1 (Sildenafilfig1)

Sildenafilfig1 (Sildenafilfig1)
A line graph depicting change in systolic blood pressure (SBP) in mmHg over time post dose (hours) comparing Doxazosin with Placebo and Doxazosin with Sildenafil 25 mg. Two lines track SBP changes up to 8 hours after dosing, showing the effects of the two treatments over time.*
FDA Label Image

Sildenafilfig2 (Sildenafilfig2)

Sildenafilfig2 (Sildenafilfig2)
A line graph showing the change in systolic blood pressure (SBP) over time post dose (hours), comparing two treatments: Doxazosin plus Placebo and Doxazosin plus Sildenafil 25 mg. The vertical axis measures change in SBP (mmHG) from -40 to 20, and the horizontal axis shows time post dose from 0 to 8 hours. The graph illustrates greater SBP reduction with Doxazosin plus Sildenafil 25 mg than with Doxazosin plus Placebo over 8 hours.*
FDA Label Image

Sildenafilfig3 (Sildenafilfig3)

Sildenafilfig3 (Sildenafilfig3)
Line graph showing change in systolic blood pressure (SBP) in mmHg over time post-dose in hours for two groups: one receiving Doxazosin with placebo and the other receiving Doxazosin with Sildenafil 50 mg. The graph depicts SBP changes from 0 to 8 hours after dosing, with the Doxazosin plus Sildenafil group showing a larger decrease in SBP compared to the placebo group.*
FDA Label Image

Sildenafilfig4 (Sildenafilfig4)

Sildenafilfig4 (Sildenafilfig4)
A line graph showing blood pressure changes over time after dosing, comparing Doxazosin plus Sildenafil 100 mg versus Doxazosin plus placebo. The x-axis represents time after dosing in hours (0 to 8), and the y-axis shows pressure in mmHg, ranging from -50 to 40. Two lines plot the pressure changes for each treatment group.*
FDA Label Image

Sildenafilfig5 (Sildenafilfig5)

Sildenafilfig5 (Sildenafilfig5)
A line graph showing plasma concentration (ng/mL) over time post dose (hours) for Sildenafil commercial tablet. The plasma concentration peaks around 1 hour post dose, then gradually declines, approaching near zero by 24 hours after dosing.*
FDA Label Image

Sildenafilfog6a (Sildenafilfog6a)

Sildenafilfog6a (Sildenafilfog6a)
A bar chart showing the percentage of patients at endpoint with varying scores represented by different shaded bars from 0 to 5. The x-axis appears to represent score values from 0 to 5, and the y-axis shows the percentage of patients, ranging from 0 to 80%. Each group of bars compares patient percentages across the different score categories.*
FDA Label Image

Sildenafilfog6b (Sildenafilfog6b)

Sildenafilfog6b (Sildenafilfog6b)
A bar chart showing the percentage of patients at endpoint across six groups labeled 0 to 5 on the horizontal axis. Each group contains multiple bars representing different subcategories, with percentages ranging from 0 to 80 on the vertical axis. A legend on the right identifies the subcategories numbered 0 through 5.*
FDA Label Image

Sildenafilfig7 (Sildenafilfig7)

Sildenafilfig7 (Sildenafilfig7)
A vertical bar chart comparing the percentage of patients reporting improvement across four treatment groups: Placebo (24%), Sildenafil Tablets 25 mg (63%), Sildenafil Tablets 50 mg (74%), and Sildenafil Tablets 100 mg (82%). The x-axis shows treatment groups with sample sizes, and the y-axis shows percentage improvement from 0 to 100 percent. Statistical significance is noted below the chart.*
FDA Label Image

72789103 Label (72789103)

72789103 Label (72789103)
Label for PD-Rx Pharmaceuticals Sildenafil USP 50 mg film-coated tablets. The label indicates a package size of 15 tablets and includes the NDC number 72789-103-15. It features dosage strength in a black box, reorder number, lot number G20D32, and expiration date 03/2022. The label includes bilingual dosage instructions and warnings to keep out of reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.